Your browser doesn't support javascript.
loading
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang, Ruijun; Verkoczy, Laurent; Wiehe, Kevin; Munir Alam, S; Nicely, Nathan I; Santra, Sampa; Bradley, Todd; Pemble, Charles W; Zhang, Jinsong; Gao, Feng; Montefiori, David C; Bouton-Verville, Hilary; Kelsoe, Garnett; Larimore, Kevin; Greenberg, Phillip D; Parks, Robert; Foulger, Andrew; Peel, Jessica N; Luo, Kan; Lu, Xiaozhi; Trama, Ashley M; Vandergrift, Nathan; Tomaras, Georgia D; Kepler, Thomas B; Moody, M Anthony; Liao, Hua-Xin; Haynes, Barton F.
Afiliação
  • Zhang R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Verkoczy L; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Munir Alam S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Nicely NI; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Santra S; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Bradley T; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Pemble CW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Zhang J; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Gao F; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bouton-Verville H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Kelsoe G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Larimore K; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
  • Greenberg PD; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Foulger A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Peel JN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Luo K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Lu X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Trama AM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Vandergrift N; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Kepler TB; Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA.
  • Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
  • Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu l.liao@dm.duke.edu.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA. Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. barton.haynes@duke.edu l.liao@dm.duke.edu.
Sci Transl Med ; 8(336): 336ra62, 2016 04 27.
Article em En | MEDLINE | ID: mdl-27122615
ABSTRACT
Development of an HIV vaccine is a global priority. A major roadblock to a vaccine is an inability to induce protective broadly neutralizing antibodies (bnAbs). HIV gp41 bnAbs have characteristics that predispose them to be controlled by tolerance. We used gp41 2F5 bnAb germline knock-in mice and macaques vaccinated with immunogens reactive with germline precursors to activate neutralizing antibodies. In germline knock-in mice, bnAb precursors were deleted, with remaining anergic B cells capable of being activated by germline-binding immunogens to make gp41-reactive immunoglobulin M (IgM). Immunized macaques made B cell clonal lineages targeted to the 2F5 bnAb epitope, but 2F5-like antibodies were either deleted or did not attain sufficient affinity for gp41-lipid complexes to achieve the neutralization potency of 2F5. Structural analysis of members of a vaccine-induced antibody lineage revealed that heavy chain complementarity-determining region 3 (HCDR3) hydrophobicity was important for neutralization. Thus, gp41 bnAbs are controlled by immune tolerance, requiring vaccination strategies to transiently circumvent tolerance controls.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Proteína gp41 do Envelope de HIV / Anticorpos Neutralizantes Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Proteína gp41 do Envelope de HIV / Anticorpos Neutralizantes Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article